Buy Tirzepatide Online — Dual Agonist from Ultima Pharmaceuticals

Also known as: Mounjaro · Zepbound · GIP/GLP-1 agonist · Dual agonist · LY3298176

Tirzepatide is a dual GIP and GLP-1 receptor agonist representing the next generation of incretin-based therapy for weight loss and type 2 diabetes. By activating two complementary hormonal pathways simultaneously it produces greater weight loss than any single-receptor agonist, with clinical trials demonstrating average reductions of up to 22% of total body weight. All Tirzepatide products at U Store are sourced from verified manufacturers, independently lab-tested, and shipped discreetly worldwide.

We found 2 products available for you.

$87.00

Ultima-Tirzepatide

Tirzepatide

1 vial x 5 mg

Clients Review:

07.01.2026

BigRezzz

grabbed one vial before it went OOS. only got to run it for 4 weeks but even in that time the results were better than anything I've experienced on semaglutide. hunger was basically gone by day 2 post injection. hoping this comes back in stock soon because i want to run a proper 6 month protocol

$189.00

TIRZEPATIDE - A-TECH LABS

Tirzepatide

1 vial x 10 mg + 1 amp sterilized water

Clients Review:

07.01.2026

JohnT

Switched to tirz after 4 months on sema. The difference is noticeable. Appetite suppression is stronger and more consistent through the week, and I'm actually losing faster at a lower dose than I was on max sema. Down 22lbs in 10 weeks at 7.5mg. The vial came with sterilized water which is convenient, reconstituted cleanly with no issues. Packaging discreet as always

About Tirzepatide

Tirzepatide is a synthetic peptide that acts as an agonist at both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. It is the first approved dual incretin receptor agonist — a new pharmacological class that goes beyond the single GLP-1 mechanism of earlier compounds like Semaglutide. With a half-life of approximately 5 days, it is administered once weekly by subcutaneous injection.

Mechanism of action

GIP and GLP-1 are both incretin hormones secreted by the gut in response to nutrient intake, but they act on different receptor populations and have complementary metabolic effects. GLP-1 receptor activation reduces appetite, slows gastric emptying, and stimulates insulin secretion. GIP receptor activation enhances insulin secretion in a glucose-dependent manner, improves insulin sensitivity in adipose tissue, and may contribute to fat oxidation. The combination of both pathways appears to be synergistic rather than simply additive, explaining the superior weight loss outcomes compared to GLP-1 monotherapy.

Weight loss outcomes

The SURMOUNT clinical trial program demonstrated that Tirzepatide at 15mg weekly produced average weight loss of approximately 22% of total body weight over 72 weeks in non-diabetic obese individuals. A significant proportion of participants — over one third — achieved weight loss exceeding 25%, outcomes that rival bariatric surgery. These results established Tirzepatide as the most effective approved pharmacological weight loss treatment curren

Use in performance sports

In performance and bodybuilding contexts Tirzepatide is used during aggressive cutting phases where maximum fat loss is the priority. Its superior appetite suppression compared to Semaglutide allows users to maintain deeper caloric deficits with less hunger and food preoccupation. Improved insulin sensitivity is an additional benefit for metabolic health during and after periods of anabolic compound use. As with Semaglutide, adequate protein intake and resistance training are essential to minimize lean mass loss during use.

Titration protocol

Tirzepatide is initiated at 2.5mg weekly and increased by 2.5mg every 4 weeks as tolerated, up to a maximum of 15mg weekly. Slower titration significantly reduces gastrointestinal side effects. Most users find their optimal dose between 5mg and 10mg weekly, balancing efficacy with tolerability.

Frequently Asked Questions

What is Tirzepatide and how does it differ from Semaglutide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist while Semaglutide is a GLP-1 receptor agonist only. By activating two complementary incretin pathways simultaneously, Tirzepatide produces greater weight loss — approximately 22% of body weight versus 15 to 17% for Semaglutide at maximum doses in clinical trials. Both require weekly subcutaneous injection and share a similar side effect profile dominated by gastrointestinal symptoms during titration.

How is Tirzepatide administered?

Tirzepatide is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. It is available in pre-filled pens at doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. The starting dose is 2.5mg weekly, increased gradually every 4 weeks to minimize side effects.

How much weight can you lose on Tirzepatide?

Clinical data from the SURMOUNT trials shows average weight loss of approximately 20 to 22% of total body weight at the 15mg dose over 72 weeks. Results depend significantly on dietary adherence and activity level — Tirzepatide is a powerful appetite and metabolic tool but not a substitute for a structured nutrition and training approach.

What are the side effects of Tirzepatide?

The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and reduced appetite — most pronounced during dose escalation and generally diminishing over time. Serious but rare risks include pancreatitis and gallbladder disease. Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.

Does Tirzepatide preserve muscle mass?

Tirzepatide does not directly cause muscle loss but the caloric deficit it induces can result in lean mass reduction without adequate protein intake and resistance training. Performance users typically combine Tirzepatide with high protein diets, structured resistance training, and in some cases anabolic compounds to protect lean mass during aggressive fat loss phases.

How does Tirzepatide compare to Retatrutide?

Tirzepatide is a dual agonist targeting GIP and GLP-1 receptors. Retatrutide is a triple agonist that additionally activates the glucagon receptor, producing even greater energy expenditure and weight loss in early clinical data. Retatrutide is newer and less widely available, while Tirzepatide has full regulatory approval and extensive real-world safety data.